Data as of Q4 2025 (Dec 31, 2025)
โณ
Showing Q1 2024 data
Altitude Crest Partners Inc.'s Q4 2025 filing not yet available. Expected by Feb 14, 2026.

Altitude Crest Partners Inc.

โ€ขCIK: 1986035โ€ขFiling: Q1 2024

**Altitude Crest Partners Inc.** manages $234M across a concentrated portfolio of 30 positions. The fund exhibits significant conviction in select names, with its top holdings including LEGN at $36.6M and DHR at $27.1M. Further allocations are notable in biotechnology and healthcare, with BBIO ($18.9M), VYLD ($17.7M), and APLS ($16.9M) representing core components of the strategy. This structure suggests a focused, high-conviction approach within specialized sectors.

Total AUM
$233.6M
QoQ Performance
+56.3%
Positions
30
Top 10 Concentration
69.3%
Latest Filing
Q1 2024

Top Holdings Allocation

LEGN
DHR
BBIO
STVN
APLS
LEGN15.7%
DHR11.6%
BBIO8.1%
STVN7.6%
APLS7.2%
TMO4.6%
AVBP4.2%
GPCR3.8%

๐Ÿ“ˆ Biggest Buys

STVN
STEVANATO GROUP S P A
NEW
7.6% of portfolio
TMO
THERMO FISHER SCIENTIFIC INC
NEW
4.6% of portfolio
AVBP
ARRIVENT BIOPHARMA INC
NEW
4.2% of portfolio
GPCR
STRUCTURE THERAPEUTICS INC
NEW
3.8% of portfolio
APLS
APELLIS PHARMACEUTICALS INC
+88.7%
7.2% of portfolio

๐Ÿ“‰ Biggest Sells

BBIO
BRIDGEBIO PHARMA INC
-18.9%
8.1% of portfolio
ROIV
ROIVANT SCIENCES LTD
-43.7%
2.1% of portfolio
DHR
DANAHER CORPORATION
-10.6%
11.6% of portfolio
KNSA
KINIKSA PHARMACEUTICALS LTD
-12.2%
3.4% of portfolio

Sector Breakdown

Other80.7%
Healthcare19.3%

๐Ÿšช Exited Positionssold since Q4 2023

ARGX
ARGENX SE
SOLD
$11.2M
BMRN
BIOMARIN PHARMACEUTICAL INC
SOLD
$11.0M
EXK
EXACT SCIENCES CORP
SOLD
$7.3M
โ€”
AMBRX BIOPHARMA INC
SOLD
$613.7K

Changes from Q4 2023

NEW22 new positions
โ†‘2 increased
โ†“4 decreased

Historical Filings

Q1 2024Q4 2023